OneSource Speci.
OneSource Speci. Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth. OneSource Specialty Pharma expects continued strong revenue and EBITDA growth beyond FY28.
From OneSource Speci.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth.
- Capacity expansions: New sterile lines coming online this quarter and end of FY27, tripling sterile days by FY28 to 675 days, enabling higher volumes.
- Expansion in drug-device combination, biologics (including animal health and biosimilars), soft gelatin capsules, and injectables to drive growth beyond FY28.
- Biologics contracts with large global players expected to contribute commercial revenues from FY29 onwards.
- Soft gelatin capacity fully utilized with new greenfield facility planned to support growth.
- Injectable business adding new capabilities (pre-filled syringes, lyophilization) to boost sales.
- Addition of new customers enabled by increased capacity; supply constraints easing.
2 more points from OneSource Speci.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what OneSource Speci. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma has committed approximately 80% of a planned US$100 million capex primarily for drug-device combination (DDC) capacity expansion.
- No significant additional capex planned for the current year beyond the balance 20% of the $100 million.
- Future biologics capacity expansion will require additional capex, but expected to be significantly lower than DDC investments.
- New capacity additions for sterile injectable lines and lyophilization are underway, including a planned shutdown in H1 FY27 to expand injectable capacity.
2 more points from OneSource Speci.'s call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Speci. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has strong visibility on its order book and capacity utilization through FY27 and towards FY28.
- Drug-device combination segment has very clear demand with customers in Canada, India, and emerging markets, supporting robust order book.
- Biologics business shows significant traction with new contracts and a strong funnel expected to convert in coming quarters.
- Soft gelatin and injectable businesses are filling capacity with new customers onboarding.
- They have enough capacity to meet existing demand and plan new capacity additions from this quarter.
2 more points from OneSource Speci.'s call on order book
Pro opens every point from 15K+ earnings calls
OneSource Speci. — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Speci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
OneSource Speci. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Speci. Q1 FY27 results?
Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth. OneSource Specialty Pharma expects continued strong revenue and EBITDA growth beyond FY28.
What is OneSource Speci. share price analysis?
OneSource Speci. currently shows a strong growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹17,602 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Speci. planning capital expenditure?
OneSource Specialty Pharma has committed approximately 80% of a planned US$100 million capex primarily for drug-device combination (DDC) capacity expansion.
Keep OneSource Speci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.